Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload
- 339 Downloads
This study of UK patients examines clinical, healthrelated quality of life (HRQOL) and economic outcomes associated with iron chelation therapy (ICT). Desferrioxamine (DFO) (Desferal®; Novartis, Switzerland) and Deferiprone (Ferriprox®; Apotex, Canada) are ICTs used to treat iron overload. DFO requires 8-to 12-hour infusions a minimum of five times per week. Deferiprone is administered in an oral daily regimen. Although pharmacologically efficacious, clinical effectiveness of ICT within the real-world setting is yet to be fully elucidated.
A naturalistic cohort study of 60 patients (betathalassaemia, n=40; sickle cell disease, n=14; myelodysplastic syndromes, n=6; 63% female) receiving ICT in four UK treatment centres was conducted. Serum ferritin level data were abstracted from medical charts. Compliance, HRQOL, satisfaction and resource utilisation data were collected from interviews. Maximum ICT costs were estimated using the resource utilisation data associated with DFO.
Mean serum ferritin levels, generally, remained elevated despite ICT. Compliance was suboptimal and HRQOL scores were lower than population norms. The total estimated mean weighted annual per-patient cost of DFO treatment was approximately £19,000. DFO-related equipment, DFO drug, and home healthcare were estimated to account for 43%, 19% and 24% of costs, respectively. Other more minor components of total annual costs were for in-patient infusions, ICT home delivery services and monitoring costs.
Generally, patients are not achieving target serum ferritin thresholds despite chronic treatment for iron overload. ICT appears to negatively impact HRQOL; compliance with ICT is poor; and, in the case of DFO, treatment costs well exceed the cost of DFO alone. These results suggest that current ICT in the real-world setting is suboptimal with respect to various clinical, HRQOL and economic outcomes.
Keywordsclinical effectiveness economic burden health-related quality of life ICT iron overload
- 2.Harvard Medical School. Effects of iron overload: hemochromatosis, tranfusional iron overload. 2006. Available at: http://sickle.bwh.harvard.edu/index.html. Accessed June 2008.
- 8.Shumaker SA, Berzon RA. The International Assessment of HRQL. Theory, Translations, Measurement and Analysis. Oxford: Rapid Communications; 1995.Google Scholar
- 18.Rofail D, Abetz L, Viala M, et al. Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed questionnaire. Value Health. 2008; Jul 11. Epub ahead of print.Google Scholar
- 20.Gold MR, Siegel JE, Russell LB, Weistein MC. Cost Effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996.Google Scholar
- 21.Zeuner D, Ades A, Karnon J, et al. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. NHS Health Technol Assess Prog. 1999;3:1–186.Google Scholar
- 22.Wayne A, Schoenike S, Pegelow C, et al. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood. 2000;96:2367–2369.Google Scholar
- 25.Jenkinson C, Stewart-Brown S, Petersen S. Assessment and Evaluation of the SF36 Version II. Health Services Research Unit: University of Oxford; 2006. Available at: www.hsru.ox.ac.uk/sf36v2.htm. Accessed 9 February 2006.Google Scholar
- 28.Landgraf JM, Abetz L, Ware JE. The Child Health Questionnaire (CHQ): a User’s Manual. 2nd ed. Boston, MA: The Health Institute; 1996.Google Scholar
- 29.Medi-Scot web site. Available at: www.mediscot.co.uk. Accessed 18 September 2006.Google Scholar
- 30.Medicines and Healthcare Products Regulatory Agency. Market survey. Nonelectrically powered dispoable infusion devices. Report 05055. September 2005. Available at: www.pasa.nhs.uk/evaluation/docs/general_medical/Report_05055 pdf. Accessed 23 October 2006.Google Scholar
- 31.Williams Medical Supplies. Available at: www wmsplc.co.uk. Accessed 18 September 2006.Google Scholar
- 32.Modell B. Guidelines for the control of haemoglobin disorders. Report of the Sixth Annual Meeting of the WHO Working Group on Haemoglobinopathies, Cagliari, Sardinia, 8–9 April 1989. Geneva: World Health Organization; 2004.Google Scholar
- 34.Curtis L, Netten A. Unit Costs of Health and Social Care 2005. The University of Kent, Personal Social Services Research Unit 202.Google Scholar
- 38.Thalassemia International Federation web site. Guidelines for Clinical Management of Thalassemia. 2000. Available at: www. thalassaemia.org.cy/MyData/Books/Clinical_%20Management_Thalassaemia.pdf. Accessed June 2008.Google Scholar